KRYS News and Press, Krystal Biotech Inc. From 12/14/22

PITTSBURGH, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that data from the pivotal Phase 3 (GEM-3)...

First, let's get one thing out of the way. Investing in small-cap stocks can be very risky. These companies aren't worth much for a reason; most investors don't see them as attractive options. And while the majority isn't always right, it is still worth it to at least consider widespread opinions...

PITTSBURGH, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) today announced that the company will participate in the investor-focused Cantor Fitzgerald Med...

PITTSBURGH, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the Bo...

PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in ...

Up to nine months durability of effect observed in patients aged 55 to 76 in the extension cohort following administration of high dose KB301 Mean change in Subject Satisfaction Scores from baseline ranged from 1.6 to 1.85 points up to nine months after dosing Company plans on i...

Krystal Biotech press release ( NASDAQ: KRYS ): Q3 GAAP EPS of -$1.17 beats by $0.05 . Cash, cash equivalents, and investments totaled $407.0 million on September 30, 2022. For further details see: Krystal Biotech GAAP EPS of -$1.17 beats by $0.05

•  Received US FDA filing acceptance of B-VEC BLA with Priority Review designation for treatment of dystrophic epidermolysis bullosa; PDUFA target action date of February 17, 2023 •  Notified of no Advisory Committee meeting or a need for Risk Evaluation an...

Summary Children suffering dystrophic epidermolysis bullosa (DEB), a serious genetic disease, are affectionately called butterfly children, depicting their fragile, recurrent blistering skin with chronic open wounds. Currently, there are three potential DEB treatments that have co...

PITTSBURGH, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene therapy, announced today that the Company will participate in the Chardan’s 6 th Annual Genetic Medicines Conference in New York...